Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kinnate Biopharma (KNTE) has provided an update.
Kinnate Biopharma Inc. has struck a deal with Pierre Fabre Médicament to sell the global rights to its pan-RAF inhibitor program, including the investigational drug exarafenib. The agreement promises Kinnate up to $31 million, with an initial $500,000 payment and further contingent payments based on developmental milestones. Pierre Fabre will also take on the ongoing costs and up to $5 million of trade payables related to the assets. The deal, which already closed without any conditions, could also lead to stockholders receiving net proceeds from the $30.5 million contingent payment, depending on the success of a separate transaction with XOMA Corporation.
Learn more about KNTE stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money